Page 2 - Aduhelm News Today

Biogen, maker of the Alzheimer's medicine Aduhelm, announced Wednesday that it would "discontinue the development and commercialization" of the controversial drug.

Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago.

Biogen discontinues Alzheimers drug Aduhelm, which has a lack of coverage amid efficacy concerns, after weighing its finances. It is redirecting efforts to Leqembi, approved by FDA in 2023.

The effects of drugs that treat Alzheimer’s, cancer and other illnesses are often limited by the blood-brain barrier. A small study suggests a way forward.

Easing access to Alzheimers diagnostic tests is critical in light of recent approvals of drugs to reduce amyloid plaque. But questions remain regarding equitable access.

Analysts say the 2024 adjustment, which helps older Americans keep up with inflation, won’t be nearly as high as this year’s but will still be significant.

"The big thing is, if this one is so much better do I want to stop for what [would] probably be a year then just to go back to [being] on that?"

One of the most frustrating and scary things about dementia is that we still know breathtakingly little about it. But the medical community in Michigan, as in the rest of the U.S., is currently working at unprecedented speed to change that.

The groundbreaking FDA-approved Alzheimer's drug, Leqembi, now covered by Medicare, offers hope and relief to millions of patients and their families.

U.S. officials have granted full approval to a closely watched Alzheimer’s drug for patients with early stages of the disease. The Food and Drug Administration decision clears the way for